The direct medical costs of epilepsy in children and young people: a population-based study of health resource utilisation
- PMID: 24447611
- DOI: 10.1016/j.eplepsyres.2013.12.014
The direct medical costs of epilepsy in children and young people: a population-based study of health resource utilisation
Abstract
We described the health resource utilisation (HRU) and associated direct medical costs of managing epilepsy in children and young people (CYP) using population-level data from the United Kingdom. The study cohort were CYP born between 1988 and 2004 who were newly diagnosed with epilepsy and identified using a nationally representative primary care database from the United Kingdom. Reference unit costs were applied to each element of HRU to calculate annual direct medical costs per child. We assessed whether HRU and costs differed by time from diagnosis, age, sex and socioeconomic deprivation. Of 798 CYP newly diagnosed with epilepsy, 56% were male and the mean age at diagnosis was 5.6 years. The highest burden of HRU was in the first year following diagnosis with a mean annual cost of £930 (95% confidence interval (CI) £839-1022) per child in this first year. This decreased to £461 (95%CI 368-551) in the second year which remained fairly constant each subsequent year (£413 (95% CI 282-540) in the 8th year). The highest contribution to the annual medical costs was from inpatient hospital admissions followed by the costs of AEDs. Mean annual medical costs were significantly higher in children under 6 years of age compared with older children (p<0.01), but were similar across socioeconomic groups (p=0.62). The direct medical costs of HRU in CYP with epilepsy are higher in the first year after diagnosis compared to subsequent years, reflecting HRU related to the diagnostic process in the first year. Medical costs did not vary substantially by sex or socioeconomic deprivation indicating a similar level of consultation and care across these groups.
Keywords: Epilepsy in children; General practice; Health resource; Medical cost.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Health care resource utilization in patients with active epilepsy.Epilepsia. 2010 May;51(5):874-82. doi: 10.1111/j.1528-1167.2009.02404.x. Epub 2009 Dec 1. Epilepsia. 2010. PMID: 20002149
-
Health resource use in epilepsy: Significant disparities by age, gender, and aboriginal status.Epilepsia. 2008 Apr;49(4):586-93. doi: 10.1111/j.1528-1167.2007.01466.x. Epub 2007 Dec 28. Epilepsia. 2008. PMID: 18177361
-
Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.Epilepsy Behav. 2013 Jun;27(3):433-8. doi: 10.1016/j.yebeh.2013.03.007. Epub 2013 Apr 13. Epilepsy Behav. 2013. PMID: 23591262
-
A review of the costs of managing childhood epilepsy.Pharmacoeconomics. 2005;23(1):27-45. doi: 10.2165/00019053-200523010-00003. Pharmacoeconomics. 2005. PMID: 15693726 Review.
-
[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].Med Klin (Munich). 1996 Jul 15;91(7):479-85. Med Klin (Munich). 1996. PMID: 8756119 Review. German.
Cited by
-
Pharmacoeconomics Aspects of Antiepileptic Drugs in Pediatric Patients with Epilepsy.Int J Environ Res Public Health. 2022 Jun 20;19(12):7517. doi: 10.3390/ijerph19127517. Int J Environ Res Public Health. 2022. PMID: 35742766 Free PMC article.
-
Hospital readmissions in children with new-onset infantile epileptic spasms syndrome.Epilepsia Open. 2023 Jun;8(2):444-455. doi: 10.1002/epi4.12711. Epub 2023 Mar 30. Epilepsia Open. 2023. PMID: 36790214 Free PMC article.
-
Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy.Saudi Pharm J. 2020 Oct;28(10):1228-1237. doi: 10.1016/j.jsps.2020.08.013. Epub 2020 Aug 21. Saudi Pharm J. 2020. PMID: 33132717 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical